<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744197</url>
  </required_header>
  <id_info>
    <org_study_id>12112</org_study_id>
    <nct_id>NCT01744197</nct_id>
  </id_info>
  <brief_title>Synera Venipuncture Pain</brief_title>
  <official_title>Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Oncology Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nuvo Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>US Oncology Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Synera, which is a heated topical patch containing both lidocaine and tetracaine, is intended
      to reduce the pain associated with venipuncture and superficial dermatologic procedures by
      numbing the skin. This study will test the effectiveness of the Synera lidocaine/tetracaine
      patch when administered for 30 Â± 5 minutes to provide dermal anesthesia in adult oncology
      patients undergoing venipuncture as part of their care, for treatment or diagnostics
      (laboratory or imaging). Compared to the use of the placebo patch, this study hypothesizes
      that the difference of 1 cm on the 0-10 visual analogue scale (VAS) will be observed 30
      minutes after the use of the Synera patch. Pain intensity will be assessed by a 0-10 VAS
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With No or Minor Pain (VAS&lt;3)</measure>
    <time_frame>30 minutes after the venipuncture.</time_frame>
    <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS &lt;3 is considered as patients with no or minor pain and would be compared between 2 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients With No Pain (VAS=0)</measure>
    <time_frame>30 minutes after the venipuncture.</time_frame>
    <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Satisfaction With Venipuncture</measure>
    <time_frame>30 minutes after the venipuncture.</time_frame>
    <description>Rates of Satisfied and very satisfied are used to be compared between two groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pain</condition>
  <condition>Phlebotomy</condition>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First application: Synera patch; Second application: Placebo patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First application: Placebo patch; Second application: Synera patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Synera (lidocaine 70mg/tetracaine 70mg)</intervention_name>
    <description>All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Synera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with any tumor type where treatment is received through venipuncture or any
             procedure that is needle based or who require regular pharmacokinetic (PK) study.

          -  Is 18 years of age or older.

          -  Patients expected to undergo the first venipuncture procedure within 5 working days of
             enrollment.

          -  Male or female patients

          -  Has signed the most recent Patient Informed Consent Form

          -  Has signed a Patient Authorization Form (HIPPA)

        Exclusion Criteria:

          -  Patients with sensitivity to lidocaine, tetracaine, or any other component of the
             product

          -  Known sensitivity to any components of test materials (sulphites and adhesives)

          -  Patients with damaged or broken skin at the designated patch site

          -  Pregnant or breastfeeding women patients

          -  Use of any immediate-release single-agent opioid product (ie, morphine, oxycodone,
             hydrocodone, hydromorphone, oxymorphone, or tramadol) or combination products
             containing acetaminophen or ibuprofen with one of these agents within 4 hours of the
             patient's visit

          -  Previous irradiation to the site of the patch
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Matson, RN, BSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research, McKesson Specialty Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura T. Guerra, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology Research, McKesson Specialty Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>19 Locations Including</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wallace MS, Kopecky EA, Ma T, Brophy F, Campbell JC. Evaluation of the depth and duration of anesthesia from heated lidocaine/tetracaine (Synera) patches compared with placebo patches applied to healthy adult volunteers. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):507-13. doi: 10.1097/AAP.0b013e3181fa69b8.</citation>
    <PMID>20975464</PMID>
  </results_reference>
  <results_reference>
    <citation>Sawyer J, Febbraro S, Masud S, Ashburn MA, Campbell JC. Heated lidocaine/tetracaine patch (Synera, Rapydan) compared with lidocaine/prilocaine cream (EMLA) for topical anaesthesia before vascular access. Br J Anaesth. 2009 Feb;102(2):210-5. doi: 10.1093/bja/aen364.</citation>
    <PMID>19151049</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 17, 2016</results_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain control</keyword>
  <keyword>Needle stick pain</keyword>
  <keyword>Venipuncture pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synera First, Then Placebo</title>
          <description>Synera (lidocaine 70mg/tetracaine 70mg): All subjects received 2 patch applications, one Synera and one placebo. These 2 patch applications were done on separate days. Subjects in this arm received Synera patch for the first application (day 1), and then placebo for the second (day 2 or after).</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Synera</title>
          <description>Synera (lidocaine 70mg/tetracaine 70mg): All subjects received 2 patch applications, one Synera and one placebo. These 2 patch applications were done on separate days. Subjects in this arm received placebo patch for the first application (day 1), and then Synera for the second (day 2 or after).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Received 1 patch</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No patch received</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Synera First, Then Placebo</title>
          <description>Synera (lidocaine 70mg/tetracaine 70mg): All subjects received 2 patch applications, one Synera and one placebo. These 2 patch applications were done on separate days. Subjects in this arm received Synera patch for the first application (day 1), and then placebo for the second (day 2 or after).</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Synera</title>
          <description>Synera (lidocaine 70mg/tetracaine 70mg): All subjects received 2 patch applications, one Synera and one placebo. These 2 patch applications were done on separate days. Subjects in this arm received placebo patch for the first application (day 1), and then Synera for the second (day 2 or after).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="11.2"/>
                    <measurement group_id="B2" value="60.3" spread="13.0"/>
                    <measurement group_id="B3" value="60.5" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With No or Minor Pain (VAS&lt;3)</title>
        <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS &lt;3 is considered as patients with no or minor pain and would be compared between 2 groups.</description>
        <time_frame>30 minutes after the venipuncture.</time_frame>
        <population>Normal completion patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Synera</title>
            <description>Treated with Synera.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treated with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With No or Minor Pain (VAS&lt;3)</title>
          <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS &lt;3 is considered as patients with no or minor pain and would be compared between 2 groups.</description>
          <population>Normal completion patients.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.0"/>
                    <measurement group_id="O2" value="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With No Pain (VAS=0)</title>
        <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.</description>
        <time_frame>30 minutes after the venipuncture.</time_frame>
        <population>Normal completion patients</population>
        <group_list>
          <group group_id="O1">
            <title>Synera</title>
            <description>Treated with Synera.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treated with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With No Pain (VAS=0)</title>
          <description>The primary efficacy endpoint is the subject's report of pain intensity regarding the venipuncture using a 0-10 VAS. The VAS =0 is considered as patients with no pain and would also be compared between 2 groups.</description>
          <population>Normal completion patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment of Satisfaction With Venipuncture</title>
        <description>Rates of Satisfied and very satisfied are used to be compared between two groups.</description>
        <time_frame>30 minutes after the venipuncture.</time_frame>
        <population>Normal completion patients</population>
        <group_list>
          <group group_id="O1">
            <title>Synera</title>
            <description>Treated with Synera.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treated with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment of Satisfaction With Venipuncture</title>
          <description>Rates of Satisfied and very satisfied are used to be compared between two groups.</description>
          <population>Normal completion patients</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0"/>
                    <measurement group_id="O2" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the whole treatment period, up to 30 days following last dose.</time_frame>
      <desc>For treated patients only, assessed at each treatment visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>Synera</title>
          <description>Treated with Synera.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treated with Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>COSTART, CTCAE v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>VERY SLIGHT ERYTHEMA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>WELL-DEFINED ERYTHEMA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melanie Matson, RN, BSN</name_or_title>
      <organization>Evergreen Hematology and Oncology</organization>
      <phone>5094642873</phone>
      <email>mmatson@evergreen4cure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

